# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

***APPLICATION NUMBER:***
**NDA 20-632/S015**

***Trade Name:*** Meridia

***Generic Name:*** sibutramine hydrochloride monohydrate

***Sponsor:*** Abbott Laboratories, Inc.

***Approval Date:*** October 8, 2002

# CENTER FOR DRUG EVALUATION AND RESEARCH

## *APPLICATION NUMBER:*
## NDA 20-632/015

### CONTENTS

| Reviews / Information Included in this NDA Review. | |
|---|---|
| Approval Letter | X |
| Approvable Letter | |
| Labeling | |
| Medical Review(s) | |
| Chemistry Review(s) | X |
| Pharmacology Review(s) | |
| Statistical Review(s) | |
| Microbiology Review(s) | |
| Clinical Pharmacology/ Biopharmaceutics Review(s) | |
| Administrative/Correspondence Document(s) | X |

# CENTER FOR DRUG EVALUATION AND RESEARCH

***APPLICATION NUMBER:***

**NDA 20-632/S015**

**APPROVAL LETTER**

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-632/S-015

Abbott Laboratories
Attention: Todd Chermak, R.Ph.
Pharmaceutical Products Regulatory Affairs
200 Abbott Park Road
D-491, AP30-1E
Abbott Park, IL 60064-6157

Dear Mr. Chermak:

Please refer to your supplemental new drug application dated April 17, 2002, received April 18, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Meridia® (sibutramine hydrochloride monohydrate) Capsules.

This supplemental application was submitted as a "Changes Being Effected (CBE) in 30 Days" supplement and provides for a change in manufacturing site for [redacted] manufacturing process. The supplement also provides for minor changes in the [redacted] sibutramine hydrochloride monohydrate manufacturing process.

We completed our review of this supplemental new drug application. This supplement is approved.

We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call James Cross, Regulatory Project Manager, at (301) 827-6381.

Sincerely,

*{See appended electronic signature page}*

Sheldon Markofsky, Ph.D.
Acting Chemistry Team Leader II, DNDC II for the
Division of Metabolic and Endocrine Drug Products, (HFD-510)
Office of New Drug Chemistry
Center for Drug Evaluation and Research

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

Sheldon Markofsky
10/8/02 11:01:35 AM

# CENTER FOR DRUG EVALUATION AND RESEARCH

*APPLICATION NUMBER:*

**NDA 20-632/S015**

## CHEMISTRY REVIEW(S)

| CHEMIST'S REVIEW | 1.ORGANIZATION | 2. NDA NUMBER |
|---|---|---|
| | DMEDP, HFD-510 | **20-632** |

| 3. NAME AND ADDRESS OF APPLICANT | 4. SUPPLEMENT NUMBER,DATE |
|---|---|
| Abbott Laboratories<br>200 Abbott Park Road<br>Abbott Park, IL (847) 937-5531 | SCM-015, 4/17/02<br><br>User Fee Date, 10/18/02<br>CBE-30 |

| 5. NAME OF THE DRUG | 6. NONPROPRIETARY NAME | 8. AMENDMENTS/REPORT,DATE |
|---|---|---|
| **Meridia** | sibutramine HCl monohydrate | |

| 7. SUPPLEMENT PROVIDES FOR: | |
|---|---|
| Site and process changes in drug substance manufacturing. | NA |

| 9. PHARMACOLOGICAL CATEGORY | 10. HOW DISPENSED | 11. RELATED IND/NDA/DMF |
|---|---|---|
| Anti-obesity | Rx | Sibutramine |

| 12. DOSAGE FORM | 13. POTENCY |
|---|---|
| Oral Capsules | 5, 10, and 15 mg |

14. CHEMICAL NAME AND STRUCTURE.

Cyclobutanemethanamine, 1-(4-chlorophenyl)-
N,N-dimethyl-(2-methylpropyl)- hydrochloride, monohydrate (±)




15. COMMENTS

This CBE-30 days supplement provides for changes in the manufacturing site and minor changes in the manufacturing process for [redacted] of the drug substance synthesis. No information is provided in the NDA supplement, all changes are given [redacted] in an amendment to DMF [redacted] A letter of authorization from [redacted] to cross-reference DMF [redacted] is given. The supplement is in accordance with BACPAC I: Intermediates in Drug Substance Synthesis, Part IV (A)(1) and (C)(1). For specific chemistry comments, see Chemistry Review #2 of DMF 6063, dated 10/1/02. DMF 6063 is adequate for this supplement.

16. CONCLUSION AND RECOMMENDATION

The CMC information provided is satisfactory. Issue an **Approval** letter.

| 17. REVIEWER NAME | 18. REVIEWER SIGNATURE | 19. DATE COMPLETED |
|---|---|---|
| Martin Haber, Ph.D. | | October 1, 2002 |

**AP** DISTRIBUTION: ORIGINAL JACKET J. Cross M. Haber

R/D Init by: Dr. Shelton Markofsky, Acting Chemistry Team Leader

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

Martin Haber
10/3/02 04:23:22 PM
CHEMIST

recommends approval

Sheldon Markofsky
10/4/02 07:58:14 AM
CHEMIST

# CENTER FOR DRUG EVALUATION AND RESEARCH

*APPLICATION NUMBER:*

# NDA 20-632/S015

# ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

DEPARTMENT OF HEALTH & HUMAN SERVICES

**Food and Drug Administration**
Center for Drug Evaluation and Research
Division of Metabolic and Endocrine Drug Products

# Memorandum

**Date:** October 7, 2002

**From:** Martin Haber, Ph.D., Review Chemist, HFD-510

**Subject:** CBE Supplement- Changes in manufacturing sites

**To:** NDA 20-632

Abbott submitted the recently approved CBE supplement SCM-015 in accordance with BACPAC I. This supplement provided for changes in the manufacturing sites for drug substance

Therefore, it could be argued that an EES might be appropriate in this particular case.

For this particular case however, the site that the manufacturing was moved to was already approved for the drug substance manufacture in the original application. Also, the site last obtained an acceptable EES report for the CSN profile on 20-FEB-2002. Therefore, the EES status of this site is not in question and an EES request is not necessary.

Martin Haber, Ph.D.
Review Chemist

R/D Init by: Dr. S. Markofsky, Acting Chemistry Team Leader

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

Martin Haber
10/7/02 02:49:55 PM
CHEMIST

Sheldon Markofsky
10/7/02 03:25:27 PM
CHEMIST

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-632/S-015

**CBE-30 SUPPLEMENT**

Abbott Laboratories
Attention: Todd Chermak
Associate Director, Regulatory Affairs
200 Abbott Park Road
D-491, AP30-1E
Abbott Park, IL 60064-6157

Dear Mr. Chermak:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Meridia® (sibutramine hydrochloride monohydrate) Capsules. Please note the following information:

| | |
|---|---|
| NDA Number/Supplement: | 20-632/S-015 |
| Date of Supplement: | April 17, 2002 |
| Date of Receipt: | April 18, 2002 |
| Filing Date: | June 17, 2002 |

This supplemental application was submitted as a "Changes Being Effected (CBE) in 30 Days" supplement and provides for a change in manufacturing site for [redacted] manufacturing process. The supplement also provides for minor changes in the [redacted] sibutramine hydrochloride monohydrate manufacturing process.

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on June 17, 2002 in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be October 18, 2002.

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:

U.S. Postal/Courier/Overnight Mail:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Metabolic and Endocrine Drug Products, HFD-510
Attention: Division Document Room
5600 Fishers Lane, 14B19
Rockville, MD 20857

If you have any questions, call me at 301-827-6381.

Sincerely,

*{See appended electronic signature page}*

James T. Cross
Regulatory Project Manager
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

James Cross
4/29/02 06:09:14 PM